The discovery of induced pluripotent stem cells (iPSCs) has opened a new channel for novel drug discovery, disease modeling, and toxicity studies. As much as iPSCs are an attractive choice in the drug discovery space, it is very important to follow best practices for iPSC research in order to maximize their potential.

In this point of view, we discuss the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control for every iPSC batch. These measures are crucial for ensuring the delivery of high-quality iPSCs across application areas to maximize drug discovery success.